COVID-19 vaccine study resumes in UK following suspected spinal issue

Alan Condon -   Print  |

Healthcare regulators in the United Kingdom gave the green light for AstraZeneca's COVID-19 vaccine clinical trial to resume Sept. 13 after a suspected spinal problem halted the study last week, WebMD reports.

Several media outlets, including The New York Times, reported that a trial participant had been diagnosed with transverse myelitis, a rare neurologic disorder.

The illness is an inflammation of the spinal cord that interrupts messages that nerves send throughout the body, according to Rochester, Minn.-based Mayo Clinic.

The U.S. portion of the clinical trial is enrolling 30,000 participants, but the study remains paused while safety data is being reviewed.

More than 18,000 individuals have received the vaccine so far, according to WebMD.

More articles on spine:
The evolution of MIS SI joint: 6 key developments since CMS upped rates 27%
Losing its orthopedic provider to a competitor, New York system taps new partner
Orthopedic rankings, robotics & more: 6 key developments at Mayo Clinic during the pandemic

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers